Plain-English translation of NCT06216847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large research study following 10,000 patients with coronary heart disease (blocked heart arteries) to learn which treatments and prevention strategies work best for different people. Researchers will collect detailed information about your heart condition, imaging scans, and medical history to build a comprehensive database that helps doctors predict which patients are at highest risk and recommend personalized treatment plans.
Even with modern treatments and prevention efforts, heart disease remains a leading cause of death worldwide, and current one-size-fits-all approaches aren't working well enough. This study aims to use advanced data analysis to identify which patients need the most aggressive care and which specific therapies prevent the worst outcomes.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to access your medical records, heart imaging results, and lab tests related to your heart condition. You would need to attend follow-up visits at the hospital over time so researchers can track how you're doing and what treatments you received. The study does not involve taking an experimental medication—instead, it observes standard care to understand which real-world treatment choices lead to the best outcomes.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Sponsor
Shenyang Northern Hospital
Enrollment target
~10,000 participants
Started
February 2024
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yi Li, MD
The General Hospital of Northern Theater Command
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.